Although long-term glucocorticoid therapy slows disease progression for DMD, the disease trajectory is still characterized by declining motor function due to progressive muscle atrophy and loss of lean muscle mass. The rate of loss of lean body mass in DMD has not been reported. To investigate the trajectory of DXA lean body mass of DMD patients compared to healthy population. IRB approved study of longitudinal whole body composition data for lean mass, fat mass and height of Healthy children (HC) from the NICHD “Bone mineral density in childhood study” 2002–2009 and DMD patients.

Read More...

Leave a comment.

Your email address will not be published. Required fields are marked*

Andoird App
Loading...